Arthritis & Rheumatism

Some RA treatments up second nonmelanoma skin cancer risk

(HealthDay)—For patients with rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) with prior nonmelanoma skin cancer (NMSC), the risk of second NMSC varies with different treatments, according to a study published ...

Oncology & Cancer

Afatinib improves progression-free survival in head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based ...

Arthritis & Rheumatism

Tofacitinib ups rheumatoid arthritis treatment response

(HealthDay)—The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs), according to a study published in the Aug. ...

Arthritis & Rheumatism

EULAR issues updated rheumatoid arthritis management recommendations

The European League Against Rheumatism (EULAR) has released updated recommendations for the management of RA. According to this latest guidance, treatment with disease-modifying anti-rheumatic drugs (DMARDs) should be initiated ...

Arthritis & Rheumatism

Abatacept as effective as adalimumab in rheumatoid arthritis

Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).

page 5 from 9